B. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc

B. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc


's stock had its "buy" rating restated by investment analysts at B. Riley in a research note issued to investors on Wednesday. They presently have a $2.30 price target on the biotechnology company's stock.



from Biotech News